BARDA contract worth up to $89M will support Basilea antibiotic

06/25/2013 | RTT News

The Biomedical Advanced Research and Development Authority granted Basilea Pharmaceutica a six-year contract worth as much as $89 million to support development of its novel monosulfactam antibiotic BAL30072. The drug, which is under development for severe infections, was chosen because of its broad coverage against multidrug-resistant Gram-negative pathogens. Basilea initially will get $17 million over 22 months.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC